Business Description
Madrigal Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US5588681057
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 9 | |||||
Equity-to-Asset | 0.79 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -13 | |||||
3-Year EPS without NRI Growth Rate | -15.2 | |||||
3-Year FCF Growth Rate | -19.5 | |||||
3-Year Book Growth Rate | 9.6 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 42.01 | |||||
9-Day RSI | 43.11 | |||||
14-Day RSI | 43.44 | |||||
6-1 Month Momentum % | 78.67 | |||||
12-1 Month Momentum % | -14.02 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.39 | |||||
Quick Ratio | 9.39 | |||||
Cash Ratio | 9.26 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -13.91 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -145 | |||||
ROA % | -85.58 | |||||
ROIC % | -2861.19 | |||||
ROC (Joel Greenblatt) % | -19337.28 | |||||
ROCE % | -104.13 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.14 | |||||
Price-to-Tangible-Book | 5.17 | |||||
EV-to-EBIT | -8.28 | |||||
EV-to-Forward-EBIT | -5.4 | |||||
EV-to-EBITDA | -8.29 | |||||
EV-to-Forward-EBITDA | -5.41 | |||||
EV-to-Forward-Revenue | 44.8 | |||||
EV-to-FCF | -9.11 | |||||
Price-to-Net-Current-Asset-Value | 5.19 | |||||
Price-to-Net-Cash | 5.28 | |||||
Earnings Yield (Greenblatt) % | -12.08 | |||||
FCF Yield % | -8.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Madrigal Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -21.368 | ||
Beta | 1.28 | ||
Volatility % | 72.49 | ||
14-Day RSI | 43.44 | ||
14-Day ATR (€) | 7.62113 | ||
20-Day SMA (€) | 199.725 | ||
12-1 Month Momentum % | -14.02 | ||
52-Week Range (€) | 113.8 - 295 | ||
Shares Outstanding (Mil) | 21.31 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Madrigal Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Madrigal Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Madrigal Pharmaceuticals Inc Frequently Asked Questions
What is Madrigal Pharmaceuticals Inc(STU:YDO1)'s stock price today?
When is next earnings date of Madrigal Pharmaceuticals Inc(STU:YDO1)?
Does Madrigal Pharmaceuticals Inc(STU:YDO1) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |